Dentsply Sirona webinar to spotlight ortho-restorative workflow
Dentsply Sirona will host a webinar presented by Dr. Mona Patel to discuss integrating clear aligner orthodontics with direct composite restoration. The session, titled “The power duo: Ortho + resto for smile mastery,” will outline a structured ortho-restorative workflow. It aims to teach participants how to use orthodontic treatment as a foundation for aesthetic dentistry and apply composite techniques post-orthodontics.
DENTSPLY SIRONA Inc. (DY2.F) Analyst insights, Price targets and Recommendations
The article provides analyst insights, price targets, and recommendations for DENTSPLY SIRONA Inc. (DY2.F), listing recent upgrades and downgrades from various financial institutions. As of April 2nd, 2026, the stock was trading at 9.97 EUR. Noteworthy actions include B of A Securities upgrading the stock from Neutral to Buy.
Director at Dentsply Sirona (XRAY) receives deferred phantom stock award
Jonathan Jay Mazelsky, a director at Dentsply Sirona (XRAY), was granted 2,644.6402 phantom stock units at a reference price of $11.34 per unit under the Directors' Deferred Compensation program. This award increases his total phantom stock balance to 17,179.8540 units, which are economically equivalent to common shares and will be settled in stock upon his termination of service as a director. This transaction is classified as a routine compensation-related acquisition rather than an open-market purchase.
JPMorgan Chase & Co. Has $5.29 Million Stock Position in DENTSPLY SIRONA Inc. $XRAY
JPMorgan Chase & Co. reduced its stake in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 19.1% in the third quarter, holding 416,856 shares valued at $5.29 million. Despite this, other institutions significantly increased their positions, raising institutional ownership to approximately 95.7%. DENTSPLY SIRONA has a market capitalization of $2.33 billion, a negative P/E ratio, and recently missed EPS estimates but beat revenue expectations, with analysts maintaining a "Hold" rating and a $14.42 consensus price target.
A Look At Dentsply Sirona (XRAY) Valuation After Soft Growth And Diminishing Returns Concerns
DENTSPLY SIRONA (XRAY) is facing investor scrutiny due to soft constant currency revenue growth and diminishing returns on capital, resulting in a significant share price decline. Despite a reported loss of US$598 million, its fair value is estimated at $45.50 against a current price of $11.47, suggesting it might be undervalued. The company operates in the dental equipment sector, relying on durable demand and recurring consumables.
Reasons to Retain DENTSPLY SIRONA Stock in Your Portfolio Now
DENTSPLY SIRONA (XRAY) is positioned for growth due to new digital-implant workflows and increased investment in research and development, despite facing headwinds from forex fluctuations and soft European demand. The company plans double-digit increases in R&D, expands its dealer network, and implements cost restructuring to reallocate funds toward debt reduction and share repurchases. However, near-term revenue decline, margin pressure from tariffs, and weakness in core segments like implants and orthodontics remain concerns for the company.
XRAY Should I Buy
Intellectia AI™ recommends a "Hold" for DENTSPLY SIRONA Inc (XRAY) for beginner investors with a long-term focus, citing a bearish trend, weak technicals, and poor financial performance in Q4 2025 despite revenue growth. While some analysts have raised price targets, the overall sentiment is mixed, and proprietary trading signals do not indicate strong buy opportunities.
Factors Supporting the Continued Inclusion of DENTSPLY SIRONA Shares in Your Investment Portfolio
Dentsply Sirona (XRAY) is positioned for growth due to its innovative digital implant solutions and increased R&D investments, despite facing challenges like unfavorable currency exchange rates and weak European demand. The company is expanding dealer partnerships and optimizing costs for long-term benefits, but short-term revenue pressures and margin compression are expected in 2026. While analysts project a revenue decrease and lower EPS for 2026, the article suggests it's a hold with potential for future improvement.
3 Reasons to Avoid XRAY and 1 Stock to Buy Instead
This article analyzes Dentsply Sirona (XRAY) and advises investors to avoid it due to declining constant currency revenue, previous growth initiatives losing money, and new investments failing to improve its Return on Invested Capital (ROIC). The company's stock is down 9.6% over the last six months, and its valuation, while seemingly cheap, is considered risky given its shaky fundamentals. Instead, the author suggests considering "one of Charlie Munger's all-time favorite businesses" and other market-beating stocks identified by StockStory's AI platform.
Dentsply Sirona (XRAY) price target increased by 11.25% to 14.71
The article reports that the price target for Dentsply Sirona (XRAY) has been increased by 11.25%, bringing it to $14.71. This indicates a more optimistic outlook on the stock's future performance.
Vanguard realignment shows 0% XRAY ownership; affiliates to report separately (XRAY)
The Vanguard Group has filed an Amendment No. 18 to a Schedule 13G/A, reporting 0 shares beneficially owned and 0% of DENTSPLY SIRONA Inc. (XRAY). This change is due to an internal realignment at Vanguard, effective January 12, 2026, which disaggregated certain subsidiaries for separate reporting in reliance on SEC Release No. 34-39538. This filing is an administrative disclosure of ownership structure, not an economic transaction, indicating that future filings from Vanguard affiliates may show redistributed holdings.
DENTSPLY SIRONA, Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1 Sh
This article focuses on the EBIT per share of DENTSPLY SIRONA, Inc. (XRAY34) as traded on the BMFBOVESPA exchange in Brazil. It presents a detailed view of its financial performance within the Health Technology and Medical Specialties sector. The content includes an overview, financials, news, community, technicals, and seasonals related to the company's stock.
Tooth File Files | Dentsply Sirona USA Vortex Blue Rotary Endo
This article from Dentsply Sirona USA introduces their Vortex Blue Rotary Endo Files. The content focuses specifically on this dental product.
Zacks Research Expects Weaker Earnings for DENTSPLY SIRONA
Zacks Research has lowered its Q1 2026 and full-year EPS estimates for DENTSPLY SIRONA (NASDAQ:XRAY), maintaining a "Hold" rating despite a mix of analyst views. While some firms have upgraded the stock, the company recently missed quarterly EPS consensus but beat on revenue, setting FY2026 guidance, and insiders have been purchasing shares. The stock's performance reflects its repricing, with analysts having a consensus "Hold" rating and a target price of $14.42.
Southpoint files 13G: 10M shares in Dentsply Sirona (NASDAQ: XRAY)
Southpoint Master Fund, LP, along with affiliated entities and John S. Clark II, has reported beneficial ownership of 10 million shares, or 5.0%, of Dentsply Sirona Inc. (NASDAQ: XRAY) common stock in a Schedule 13G filing. This passive investment indicates shared voting and dispositive power over the shares. The ownership percentage is calculated based on 199,749,333 shares outstanding as of February 20, 2026.
Jim Cramer on DENTSPLY SIRONA: “I think it absolutely represents some value here”
Jim Cramer has expressed a positive sentiment towards DENTSPLY SIRONA, indicating that he believes the stock currently offers good value. He suggests that investors might consider the company's shares as an attractive opportunity. This statement likely comes from an analysis of the company's financial standing and market position.
First-ever dental MRI machine receives FDA clearance
Dentsply Sirona and Siemens Healthineers have announced that their MAGNETOM Free.Max Dental Edition, the first-ever MRI system for dentistry, has received US
A Look At Dentsply Sirona (XRAY) Valuation After FDA Clearance For New Dental MRI System
Dentsply Sirona (XRAY) shares are attracting attention after the company, in collaboration with Siemens Healthineers, received FDA clearance for MAGNETOM Free.Max Dental Edition, a pioneering dental MRI system. Despite a recent 1-year decline in total shareholder return, the stock is currently trading below its estimated intrinsic value and analyst targets, suggesting potential upside. The article highlights the company's position as a major dental equipment provider and its valuation given the latest developments.
A Look At Dentsply Sirona (XRAY) Valuation After FDA Clearance For New Dental MRI System
Dentsply Sirona (XRAY) shares are in focus after the company received FDA clearance for MAGNETOM Free.Max Dental Edition, a new dental dedicated MRI system. Despite recent positive momentum, XRAY shares trade well below an estimated intrinsic value of $45.50 and analyst targets, suggesting potential upside, but also facing challenges like an 18.57% decline in total shareholder return over the past year and a US$598 million net loss. The article highlights that Dentsply Sirona is considered undervalued by 73.1%, but also points out key risks.
Dentsply Sirona Inc (XRAY) Shares Up 5.24% on Mar 17
Dentsply Sirona Inc (XRAY) shares rose 5.24% on March 17, reaching an intraday high of $12.38 before closing at $12.35. This places the stock 28.14% below its 52-week high and 25.33% above its 52-week low. Wall Street analysts have an average one-year target price of $14.32 for XRAY, implying a 16.01% upside from the current price, with a consensus "Hold" recommendation.
Is Dentsply Sirona's (XRAY) Dental‑Dedicated MRI Bet Quietly Redefining Its Competitive Moat?
Dentsply Sirona, in collaboration with Siemens Healthineers, has received US FDA clearance for the MAGNETOM Free.Max Dental Edition, the first dental-dedicated MRI system. This non-ionizing imaging platform could significantly enhance diagnostic capabilities across various dental specialties, bolstering Dentsply Sirona's innovation narrative. While promising for long-term growth, the technology's impact on immediate revenue growth and existing market challenges remains to be seen.
Is Dentsply Sirona's (XRAY) Dental‑Dedicated MRI Bet Quietly Redefining Its Competitive Moat?
Dentsply Sirona and Siemens Healthineers have received FDA clearance for the MAGNETOM Free.Max Dental Edition, the first dental-dedicated MRI system. This non-ionizing MRI could enhance diagnostics in various dental specialties and influence Dentsply Sirona's investment narrative by potentially offsetting revenue pressure and margin headwinds. While the technology is promising for innovation, near-term risks like soft elective demand and tariff costs still pose challenges for the company.
Invenomic Capital Management LP Increases Stake in DENTSPLY SIRONA Inc. $XRAY
Invenomic Capital Management LP significantly increased its stake in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 48.7% during the third quarter, now owning 4,351,199 shares valued at $55.2 million, making it their second-largest holding. This move comes as company insiders have also been buying shares, with Director Gregory T. Lucier purchasing 15,000 shares and Director James D. Forbes buying 5,000 shares. DENTSPLY SIRONA reported revenue above estimates but narrowly missed EPS expectations, setting FY2026 guidance and maintaining a consensus analyst price target of $14.42.
Crawford Investment Counsel Inc. Acquires Shares of 87,007 DENTSPLY SIRONA Inc. $XRAY
Crawford Investment Counsel Inc. has acquired a new stake of 87,007 shares in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) during the third quarter, valued at approximately $1.104 million. Other institutional investors have also adjusted their positions in the medical instruments supplier. DENTSPLY SIRONA recently reported quarterly earnings, missing analyst estimates, and has received varied analyst ratings, with an average "Hold" recommendation.
Crawford Investment Counsel Inc. Acquires Stake in DENTSPLY SIRONA
Crawford Investment Counsel Inc. has acquired a new stake of 87,007 shares in DENTSPLY SIRONA Inc. (NASDAQ:XRAY), valued at approximately $1,104,000, during the 3rd quarter. This acquisition suggests the investment firm perceives growth potential in DENTSPLY SIRONA, a leading global manufacturer of professional dental products and technologies.
Is Dentsply Sirona (XRAY) Offering An Opportunity After Multi Year Share Price Slump
Dentsply Sirona (XRAY) has experienced a significant share price slump over the last several years, with returns down 22.2% over 1 year and 79.5% over 5 years. Despite this, Simply Wall St's valuation model suggests the stock is currently undervalued, with a discounted cash flow analysis indicating a potential 60.4% undervaluation compared to its intrinsic value of $29.11 per share. The company's Price/Sales ratio of 0.63x is also significantly below the industry average, further supporting a potential undervaluation.
Is Dentsply Sirona (XRAY) Offering An Opportunity After Multi Year Share Price Slump
Dentsply Sirona (XRAY) has experienced a significant share price decline over the past few years, prompting an analysis of its current valuation. Simply Wall St's analysis, utilizing discounted cash flow and price-to-sales ratios, suggests the stock is undervalued, with an estimated intrinsic value considerably higher than its current market price. The article also presents bull and bear case narratives, offering different perspectives on the company's future potential.
Is Dentsply Sirona (XRAY) Offering An Opportunity After Multi Year Share Price Slump
Dentsply Sirona (XRAY) has experienced a significant multi-year share price slump, with declines of 65.8% over 3 years and 79.5% over 5 years, prompting investors to question its current valuation. According to Simply Wall St's analysis, the stock appears significantly undervalued, scoring full marks across various metrics. A discounted cash flow (DCF) analysis suggests it is 60.4% undervalued, while its Price/Sales ratio of 0.63x is well below industry and peer averages, indicating potential opportunity.
Dentsply Sirona Board Member Increases Stake with $187k Purchase | March 2026 - News and Statistics
Dentsply Sirona Director Gregory T. Lucier purchased 15,000 shares of the company's common stock for approximately $187,000 on March 9, 2026. This transaction increased his indirect holdings to over 24.9 million shares, despite the company's stock having declined over the past year. Dentsply Sirona is a global manufacturer of dental equipment and consumables, reporting $3.68 billion in trailing twelve-month revenue and a net loss for the same period.
DENTSPLY SIRONA (XRAY) EVP granted 829.396 phantom stock units
DENTSPLY SIRONA Inc.'s EVP and Chief Commercial Officer, Aldo Mariano Roberto Denti, was granted 829.396 phantom stock units under the company's Supplemental Executive Retirement Plan for 2025. These units are economically equivalent to common stock and become payable in common stock upon the termination of his employment. This transaction increases his reported phantom stock balance to 829.396 shares and was detailed in a Form 4 SEC filing.
Dentsply Sirona’s Free Cash Flow Collapsed 63%: Here’s What To Expect
Dentsply Sirona (XRAY) is undergoing an aggressive commercial reset after its free cash flow collapsed by 63% in 2025, falling from $280 million to $104 million. The company is implementing a $120 million restructuring plan, eliminating its dividend to redirect funds towards debt and share repurchases, and targeting annualized savings while reinvesting in clinical education and R&D. Wall Street analysts are cautiously optimistic, projecting a significant recovery in free cash flow for 2026 and an implied upside of 22.3% from its current price, assuming successful execution of its "Return-to-Growth" strategy despite ongoing risks, particularly in the Chinese market.
Magnetar Financial Boosts DENTSPLY SIRONA Stake
Investment firm Magnetar Financial LLC significantly increased its stake in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 539.9% in the third quarter of 2026, acquiring an additional 173,428 shares. The firm now owns 205,549 shares valued at $2.6 million, signaling a strong belief in the medical instruments supplier's potential. This substantial increase in holdings could influence DENTSPLY SIRONA's future strategic direction.
A Look At Dentsply Sirona (XRAY) Valuation After Earnings Miss And Softer 2026 Outlook
Dentsply Sirona (XRAY) shares have experienced volatility following an earnings miss, significant impairment charges, and a cautious 2026 outlook, despite higher Q4 sales. The company is implementing active cost reduction programs and operational streamlining to improve EBITDA margins and cash flow, aiming for a fair value of $14.43 against a current price of $12.74. Investors are advised to consider the underlying data, including weak U.S. sales and rising tariff costs, when evaluating the company's potential recovery.
Gamco Investors Boosts Stake in DENTSPLY SIRONA
Gamco Investors INC. ET AL has increased its stake in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 38.5% in the third quarter of 2026, bringing its total holdings to 158,803 shares valued at $2,015,000. This move signals Gamco's confidence in the dental equipment manufacturer's performance and future prospects, seeing value in the stock at current levels. DENTSPLY SIRONA is a leading global manufacturer of professional dental products, headquartered in Charlotte, North Carolina.
American Century Companies Inc. Boosts Stake in DENTSPLY SIRONA Inc.
American Century Companies Inc. has increased its stake in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 19.8% during the 3rd quarter, acquiring an additional 248,457 shares to hold a total of 1,503,145 shares valued at $19,075,000. This move signals confidence in the medical instruments supplier's long-term prospects despite mixed analyst sentiment and recent volatility. The increased investment by a major institutional investor suggests potential opportunities for other investors to examine the company.
American Century Companies Inc. Has $19.08 Million Position in DENTSPLY SIRONA Inc. $XRAY
American Century Companies Inc. increased its stake in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 19.8% during the third quarter, bringing its total holding to over 1.5 million shares valued at $19.08 million. Other institutional investors also adjusted their positions in the company, which recently received positive news regarding FDA clearance for a dental-dedicated MRI and insider stock purchases. Analysts, however, have provided mixed ratings, with an average target price of $14.42 and a "Hold" consensus.
Dentsply Sirona (XRAY) CAO awarded 2,853 phantom stock SERP units
Dentsply Sirona's VP and Chief Accounting Officer, Kevin Czerney, was awarded 2,853.551 phantom stock units under the company's Supplemental Executive Retirement Plan (SERP). These phantom shares are economically equivalent to common stock and will become payable in common stock upon the termination of his employment. Following this award, Czerney now holds a total of 6,346.9846 phantom stock shares.
Director James Forbes buys 5,000 DENTSPLY SIRONA (XRAY) shares
DENTSPLY SIRONA Inc. director James D. Forbes purchased 5,000 shares of the company's common stock at $12.48 per share on March 9, 2026. This open-market transaction increased his direct ownership to 10,000 common shares. The details of this insider trade were reported in a Form 4 filing with the SEC.
DENTSPLY SIRONA (NASDAQ:XRAY) Director Gregory Lucier Acquires 15,000 Shares
DENTSPLY SIRONA (NASDAQ:XRAY) Director Gregory Lucier acquired 15,000 shares of the company's stock on March 9th at an average price of $12.45, totaling $186,750, increasing his direct holdings by 30% to 65,000 shares. This transaction follows the company's recent earnings report where it missed EPS estimates but beat revenue expectations, and issued FY2026 guidance. Analysts currently have a "Hold" rating on the stock with a consensus price target of $14.42.
Dentsply Sirona and Siemens Healthineers Announce FDA Clearance of First Dental-Dedicated MRI System, MAGNETOM Free.Max Dental Edition
Dentsply Sirona and Siemens Healthineers have announced that their jointly developed MAGNETOM Free.Max Dental Edition, the first dental-dedicated MRI system, has received FDA clearance in the U.S. This innovation offers non-ionizing imaging that enhances diagnosis and treatment planning in various dental specialties like endodontics and orthodontics. The system features specialized dental coils and software for efficient imaging, and clinicians can attend a training program in April 2026 at the University of Minnesota.
First-ever Dental Dedicated MRI Validated in Clinical Trial and Cleared by FDA for Advanced Soft-Tissue Diagnostics
Dentsply Sirona and Siemens Healthineers have announced that their dental-dedicated MRI (ddMRI) system, MAGNETOM Free.Max Dental Edition, has received FDA clearance after successful clinical trials. This system offers non-ionizing imaging for various dental specialties, enhancing diagnosis and treatment planning with advanced soft tissue contrast. It is designed to be an efficient tool for dental professionals, providing detailed insights into dental structures and pathological processes without the risks of ionizing radiation.
New dental MRI scans jaws without ionizing radiation after FDA nod
Dentsply Sirona and Siemens Healthineers have received FDA clearance for the MAGNETOM Free.Max Dental Edition, the first dental-dedicated MRI system. This new technology offers non-ionizing imaging to enhance diagnosis and treatment planning across various dental specialties, including endodontics, periodontics, and TMJ, with an average workflow time of under 20 minutes. Training programs and demonstrations are scheduled for April 2026 and at ADEA in March 2026, targeting hospitals, large clinics, and universities.
Dentsply Sirona and Siemens Healthineers Announce FDA Clearance of First Dental-Dedicated MRI System, MAGNETOM Free.Max Dental Edition
Dentsply Sirona and Siemens Healthineers have announced FDA clearance for their MAGNETOM Free.Max Dental Edition, the first dental-dedicated MRI system, in the U.S. This system offers non-ionizing imaging for enhanced diagnosis and treatment planning in various dental specialties, including endodontics and orthodontics. Clinical trials validated its potential, highlighting its specialized dental coil, software, and efficient workflow, with advanced training opportunities available for clinicians.
Dentsply Sirona Stock Soars 15.5%, Hits Intraday High of $14.76
Dentsply Sirona, Inc. has seen a significant stock price surge of 15.5%, reaching an intraday high of $14.76, contrasting with a slight S&P 500 decline. While the company shows strong short-term gains and positive year-to-date performance, it faces longer-term challenges evident in its three-year decline and low profitability metrics. Key financial metrics include a P/E ratio of 9.00 and a 4.13% dividend yield, though Return on Capital Employed (ROCE) is low at 6.38% and debt-to-equity is high.
180,542 Shares in DENTSPLY SIRONA Inc. $XRAY Acquired by Neo Ivy Capital Management
Neo Ivy Capital Management recently acquired 180,542 shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) valued at approximately $2,291,000, representing a 0.09% stake in the company. Other institutional investors have also adjusted their holdings in the medical instruments supplier, which reported Q4 earnings of $0.27 per share, missing consensus estimates by $0.01. The company also declared a quarterly dividend of $0.16 per share, paid on January 9th.
Quantbot Technologies LP Sells 114,223 Shares of DENTSPLY SIRONA Inc. $XRAY
Quantbot Technologies LP significantly reduced its stake in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by selling 114,223 shares in the third quarter, decreasing its holdings by 62.6%. This leaves the firm with 68,202 shares valued at approximately $865,000. Other institutional investors have shown mixed activity, while the company reported Q3 earnings per share of $0.27 (missing estimates) and revenue of $961M (beating estimates), with a "Hold" consensus rating from analysts.
Dentsply Sirona gains as BofA upgrades to buy on risk-reward setup
Dentsply Sirona (NASDAQ: XRAY) shares are rising following an upgrade from BofA to Buy from Neutral, with a price target increase to $42 from $37. The upgrade is based on an attractive risk-reward setup, reflecting that the company has likely reset expectations. BofA anticipates that the core dental market will recover in 2024 and 2025.
Dentsply Sirona gains as BofA upgrades to buy on risk-reward setup
Dentsply Sirona (XRAY) saw its stock rise after BofA Global Research upgraded it from neutral to buy, citing an improved risk-reward profile. The upgrade is driven by confidence in the company's ability to achieve its full potential and leverage its strong competitive standing in the dental market. This positive outlook from BofA reflects a belief that the company is well-positioned for future growth.
DENTSPLY SIRONA (XRAY) Is Up 5.0% After Impairment Charges And New Guidance Reset Expectations – What’s Changed
DENTSPLY SIRONA (XRAY) recently saw a 5.0% stock increase after reporting Q4 2025 results, which included sales of US$961 million, a net loss of US$146 million, and significant non-cash impairment charges due to weak demand. Despite these challenges, the company issued new 2026 sales guidance of US$3.5–3.6 billion and expanded its distribution partnership with Burkhart Dental Supply. Investors are monitoring whether DENTSPLY SIRONA's digital dentistry and implant businesses can overcome persistent losses and stabilize volumes, especially given the ongoing risk of further write-downs if demand remains soft.
DENTSPLY SIRONA Inc. $XRAY Shares Bought by Kingsview Wealth Management LLC
Kingsview Wealth Management LLC significantly increased its stake in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 812.3% during the third quarter, acquiring an additional 157,448 shares. This substantial investment, bringing their total to 176,832 shares valued at approximately $2.2 million, suggests the firm's strong confidence in the medical instrument supplier's future potential. The move indicates growing institutional belief in DENTSPLY SIRONA, a major global manufacturer of dental products.
